"Cholangiocarcinoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant tumor arising from the epithelium of the BILE DUCTS.
| Descriptor ID |
D018281
|
| MeSH Number(s) |
C04.557.470.200.025.450
|
| Concept/Terms |
Cholangiocarcinoma- Cholangiocarcinoma
- Cholangiocarcinomas
- Cholangiocellular Carcinoma
- Carcinoma, Cholangiocellular
- Carcinomas, Cholangiocellular
- Cholangiocellular Carcinomas
Extrahepatic Cholangiocarcinoma- Extrahepatic Cholangiocarcinoma
- Cholangiocarcinoma, Extrahepatic
- Cholangiocarcinomas, Extrahepatic
- Extrahepatic Cholangiocarcinomas
Intrahepatic Cholangiocarcinoma- Intrahepatic Cholangiocarcinoma
- Cholangiocarcinoma, Intrahepatic
- Cholangiocarcinomas, Intrahepatic
- Intrahepatic Cholangiocarcinomas
|
Below are MeSH descriptors whose meaning is more general than "Cholangiocarcinoma".
Below are MeSH descriptors whose meaning is more specific than "Cholangiocarcinoma".
This graph shows the total number of publications written about "Cholangiocarcinoma" by people in this website by year, and whether "Cholangiocarcinoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 |
| 1995 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 2 | 4 |
| 2004 | 2 | 0 | 2 |
| 2005 | 3 | 1 | 4 |
| 2006 | 3 | 1 | 4 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 2 | 4 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholangiocarcinoma" by people in Profiles.
-
Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol. 2023 04; 34(4):702-709.
-
Risk Factors for Abscess Development Following Percutaneous Microwave Ablation Therapy of Hepatic Tumors. Cardiovasc Intervent Radiol. 2023 Jun; 46(6):726-736.
-
Neoadjuvant therapy use and association with postoperative outcomes and overall survival in patients with extrahepatic cholangiocarcinoma. J Surg Oncol. 2023 Jan; 127(1):90-98.
-
Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: Long-Term Follow-up for a 136-Patient Cohort. Cardiovasc Intervent Radiol. 2022 Aug; 45(8):1117-1128.
-
The New Era of Liver Transplantation for Cholangiocarcinoma: No Longer Just a 1-Man Show. Liver Transpl. 2022 03; 28(3):355-356.
-
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021 Nov 01; 7(11):1669-1677.
-
Endovascular management of portal vein obstruction in hepatobiliary cancer patients. J Surg Oncol. 2022 Mar; 125(3):392-398.
-
Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. Cancer Discov. 2021 05; 11(5):1248-1267.
-
Lymphoepithelioma-Like Carcinomas: A Rare Variant of Cholangiocarcinoma. Hepatology. 2020 07; 72(1):353-355.
-
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807.